National Institute on Drug Abuse; Notice of Closed Meetings, 79938 [2024-22526]
Download as PDF
<![CDATA[
79938
Federal Register / Vol. 89, No. 190 / Tuesday, October 1, 2024 / Notices
(Catalogue of Federal Domestic Assistance
Program Nos. 93.392, Cancer Construction;
93.393, Cancer Cause and Prevention
Research; 93.394, Cancer Detection and
Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology
Research; 93.397, Cancer Centers Support;
93.398, Cancer Research Manpower; 93.399,
Cancer Control, National Institutes of Health,
HHS)
Dated: September 25, 2024.
David W. Freeman,
Supervisory Program Analyst, Office of
Federal Advisory Committee Policy.
[FR Doc. 2024–22438 Filed 9–30–24; 8:45 am]
BILLING CODE 4140–01–P
Contact Person: Sudhirkumar U.
Yanpallewar, M.D., Scientific Review Officer,
Scientific Review Branch, National Institute
on Drug Abuse, NIH, 301 North Stonestreet
Avenue, MSC 6021, Bethesda, MD 20892,
(301) 443–4577, sudhirkumar.yanpallewar@
nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.277, Drug Abuse Scientist
Development Award for Clinicians, Scientist
Development Awards, and Research Scientist
Awards; 93.278, Drug Abuse National
Research Service Awards for Research
Training; 93.279, Drug Abuse and Addiction
Research Programs, National Institutes of
Health, HHS)
Dated: September 26, 2024.
Lauren A. Fleck,
Program Analyst, Office of Federal Advisory
Committee Policy.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
[FR Doc. 2024–22526 Filed 9–30–24; 8:45 am]
National Institutes of Health
BILLING CODE 4140–01–P
National Institute on Drug Abuse;
Notice of Closed Meetings
khammond on DSKJM1Z7X2PROD with NOTICES
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel; NIDA–
L conflict SEP.
Date: November 5, 2024.
Time: 1:00 p.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute of Health,
National Institute on Drug Abuse, 301 North
Stonestreet Avenue, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Sudhirkumar U.
Yanpallewar, M.D., Scientific Review Officer,
Scientific Review Branch, National Institute
on Drug Abuse, NIH, 301 North Stonestreet
Avenue, MSC 6021, Bethesda, MD 20892,
(301) 443–4577, sudhirkumar.yanpallewar@
nih.gov.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel;
Mechanism for Time-Sensitive Drug Abuse
Research.
Date: November 12, 2024.
Time: 1:30 p.m. to 2:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute of Health,
National Institute on Drug Abuse, 301 North
Stonestreet Avenue, Bethesda, MD 20892
(Virtual Meeting).
VerDate Sep<11>2014
17:42 Sep 30, 2024
Jkt 265001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Substance Abuse and Mental Health
Services Administration
Notice of Meeting for the
Interdepartmental Serious Mental
Illness Coordinating Committee
(ISMICC)
Substance Abuse and Mental
Health Services Administration,
Department of Health and Human
Services.
ACTION: Notice.
AGENCY:
The Secretary of Health and
Human Services announces a meeting of
the Interdepartmental Serious Mental
Illness Coordinating Committee
(ISMICC).
The meeting will provide information
on federal efforts related to serious
mental illness (SMI) and serious
emotional disturbance (SED); and
Report Outs from Focus Area 1—Data
and Evaluation; Focus Area 2—Access
and Engagement; Focus Area 3—
Treatment and Recovery; Focus Area
4—Criminal Justice, and Focus Area 5—
Finance; and updates on SAMHSA’s
initiatives.
DATES: October 29, 2024, 9:00 a.m. to
4:00 p.m. (EDT)/Open.
ADDRESSES: The meeting is open to the
public and can be accessed virtually
only by accessing: https://
www.zoomgov.com/j/1604912525?pwd=
XrfbvgFJM7BnfEq1xJIHRgiIsCKaEF.1 or
by dialing 646–828–7666, webinar ID:
160 491 2525, passcode: 689916.
Agenda with call-in information will be
posted on the SAMHSA website prior to
the meeting at https://www.samhsa.gov/
about-us/advisory-councils/meetings.
SUMMARY:
PO 00000
Frm 00054
Fmt 4703
Sfmt 4703
FOR FURTHER INFORMATION CONTACT:
Pamela Foote, ISMICC Designated
Federal Officer, SAMHSA, 5600 Fishers
Lane, Rockville, MD 20857; telephone:
240–276–1279; email: pamela.foote@
samhsa.hhs.gov.
SUPPLEMENTARY INFORMATION:
I. Background and Authority
The ISMICC was established on
March 15, 2017, in accordance with
section 6031 of the 21st Century Cures
Act, and the Federal Advisory
Committee Act, 5 U.S.C. App., as
amended, to report to the Secretary,
Congress, and any other relevant federal
department or agency on advances in
SMI and SED, research related to the
prevention of, diagnosis of, intervention
in, and treatment and recovery of SMIs,
SEDs, and advances in access to services
and supports for adults with SMI or
children with SED. In addition, the
ISMICC will evaluate the effect federal
programs related to SMI and SED have
on public health, including public
health outcomes such as: (A) rates of
suicide, suicide attempts, incidence and
prevalence of SMIs, SEDs, and
substance use disorders, overdose,
overdose deaths, emergency
hospitalizations, emergency room
boarding, preventable emergency room
visits, interaction with the criminal
justice system, homelessness, and
unemployment; (B) increased rates of
employment and enrollment in
educational and vocational programs;
(C) quality of mental and substance use
disorders treatment services; or (D) any
other criteria determined by the
Secretary. Finally, the ISMICC will
make specific recommendations for
actions that agencies can take to better
coordinate the administration of mental
health services for adults with SMI or
children with SED. Not later than one
(1) year after the date of enactment of
the 21st Century Cures Act, and five (5)
years after such date of enactment, the
ISMICC shall submit a report to
Congress and any other relevant federal
department or agency.
II. Membership
This ISMICC consists of federal
members listed below or their
designees, and non-federal public
members.
Federal Membership: Members
include, The Secretary of Health and
Human Services; The Assistant
Secretary for Mental Health and
Substance Use; The Attorney General;
The Secretary of the Department of
Veterans Affairs; The Secretary of the
Department of Defense; The Secretary of
the Department of Housing and Urban
E:\FR\FM\01OCN1.SGM
01OCN1
]]>Agencies
[Federal Register Volume 89, Number 190 (Tuesday, October 1, 2024)]
[Notices]
[Page 79938]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-22526]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute on Drug Abuse; Notice of Closed Meetings
Pursuant to section 1009 of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel; NIDA-L conflict SEP.
Date: November 5, 2024.
Time: 1:00 p.m. to 3:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institute of Health, National Institute on Drug
Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual
Meeting).
Contact Person: Sudhirkumar U. Yanpallewar, M.D., Scientific
Review Officer, Scientific Review Branch, National Institute on Drug
Abuse, NIH, 301 North Stonestreet Avenue, MSC 6021, Bethesda, MD
20892, (301) 443-4577, [email protected].
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel; Mechanism for Time-Sensitive Drug Abuse Research.
Date: November 12, 2024.
Time: 1:30 p.m. to 2:30 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institute of Health, National Institute on Drug
Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual
Meeting).
Contact Person: Sudhirkumar U. Yanpallewar, M.D., Scientific
Review Officer, Scientific Review Branch, National Institute on Drug
Abuse, NIH, 301 North Stonestreet Avenue, MSC 6021, Bethesda, MD
20892, (301) 443-4577, [email protected].
(Catalogue of Federal Domestic Assistance Program Nos. 93.277, Drug
Abuse Scientist Development Award for Clinicians, Scientist
Development Awards, and Research Scientist Awards; 93.278, Drug
Abuse National Research Service Awards for Research Training;
93.279, Drug Abuse and Addiction Research Programs, National
Institutes of Health, HHS)
Dated: September 26, 2024.
Lauren A. Fleck,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2024-22526 Filed 9-30-24; 8:45 am]
BILLING CODE 4140-01-P
